EGFR mutation

P2, N=50, Recruiting, Taipei Medical University Hospital | Not yet recruiting --> Recruiting

Our findings demonstrate that compound EGFR mutations comprise distinct subgroups with unique clinical characteristics and different responses to targeted therapy. For example, osimertinib may be a viable treatment for patients with compound G719X/L861Q mutations. Further characterization of these heterogeneous subgroups is warranted for identifying optimal treatment strategies as novel targeted agents emerge.

Therefore, we elucidate the mechanisms of immune resistance in EGFR-mutant patients and analyze the core immune mechanisms underlying EGFR-TKI resistance. We summarize the application of immune checkpoint inhibitors (ICIs) in advanced EGFR-mutant NSCLC and analyze the associated mechanisms of action.

CT-detected multiple subsolid nodules are associated with a slightly poorer prognosis than single subsolid nodules, resist simplistic classification as multiple primary lung cancers, and exhibit a high EGFR mutation rate that supports targeted therapy as a treatment option.

Mechanistic studies implicate drug-tolerant persister cells, spatially heterogeneous resistant clones, and supportive tumor microenvironments as key drivers of treatment failure, providing a rationale for early eradication of residual lesions. Across randomized trials and real-world cohorts, LCT has consistently been associated with improved progression-free survival and, in selected patients, overall survival, without excessive toxicity.With advances in circulating tumor DNA, metabolic imaging, and molecular profiling, LCT may evolve from a morphology-based approach into a biomarker-guided precision strategy integrated with modern systemic therapy.

In a small-sample-size test, the ESEA system achieved 100% sensitivity and specificity in pleural effusion samples (n=5) and a 100% ctDNA detection rate in patients with extracranial lesions and disease progression (n=6). These results highlight its potential as a cost-effective, highly sensitive, and robust platform for dynamic, real-time companion diagnostics, as well as non-invasive monitoring of treatment response and tumor evolution.

P=N/A, N=20, Suspended, M.D. Anderson Cancer Center

Performing molecular testing (in the absence of adequate tumor tissue with liquid biopsy) as early as possible is already an integral part of the treatment pathway planning for CCA patients. Early molecular testing may therefore lead to the possibility of administering targeted therapy in the first-line setting within this patient group, pending the outcomes of clinical trials.

SBRT combined with systemic therapy demonstrates encouraging survival and LC with acceptable toxicity. in OMD/OprogD NSCLC. Longest survival correlates more strongly with favorable tumor biology than treatment timing, supporting biomarker-driven patient selection. Future randomized trials should validate these patterns and establish precision-based treatment algorithms.

An ongoing phase 2 trial evaluating first-line sac-TMT plus osimertinib combination therapy in patients with advanced EGFR-mutant NSCLC shows preliminary efficacy. Together, our findings establish TROP2 as a therapeutically actionable vulnerability in DTP cells and support the clinical development of TROP2-ADC combined with EGFR-TKI as a first-line strategy to delay TKI resistance and improve outcomes in EGFR-mutant NSCLC.

P1/2, N=16, Recruiting, Misty Shields | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Aug 2026

P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027